SLXN (Silexion Therapeutics) Other Long Term Assets : $0.05 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics Other Long Term Assets?

Silexion Therapeutics's other long-term assets for the quarter that ended in Dec. 2024 was $0.05 Mil.

Silexion Therapeutics's quarterly other long-term assets declined from Jun. 2024 ($0.03 Mil) to Sep. 2024 ($0.01 Mil) but then increased from Sep. 2024 ($0.01 Mil) to Dec. 2024 ($0.05 Mil).

Silexion Therapeutics's annual other long-term assets increased from Dec. 2022 ($0.03 Mil) to Dec. 2023 ($0.03 Mil) and increased from Dec. 2023 ($0.03 Mil) to Dec. 2024 ($0.05 Mil).

Silexion Therapeutics Other Long Term Assets Historical Data

The historical data trend for Silexion Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics Other Long Term Assets Chart

Silexion Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Other Long Term Assets

0.03

0.05

Silexion Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Long Term Assets	Get a 7-Day Free Trial				0.03	0.03	0.03	0.01	0.05

Silexion Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Silexion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Abba Hillel Road, Ramat-Gan, ISR, 5250606

Website

https://silexion.com

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.